FibroGen (NASDAQ:FGEN) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of FibroGen (NASDAQ:FGEN) in a research note released on Wednesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the stock. HC Wainwright upgraded shares of FibroGen to a “strong-buy” rating in a research note on Tuesday, December 17th. William Blair reissued a “market perform” rating on shares of FibroGen in a report on Wednesday, November 13th.

FibroGen Trading Up 9.5 %

FGEN stock opened at $0.51 on Wednesday. The firm has a 50 day simple moving average of $0.48 and a 200-day simple moving average of $0.45. The company has a market capitalization of $51.09 million, a P/E ratio of -0.41 and a beta of 0.75. FibroGen has a twelve month low of $0.18 and a twelve month high of $2.93.

FibroGen (NASDAQ:FGEN) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.21. The firm had revenue of $46.33 million for the quarter, compared to the consensus estimate of $34.00 million. During the same period in the prior year, the business earned ($0.52) EPS. On average, research analysts predict that FibroGen will post -0.8 EPS for the current year.

Hedge Funds Weigh In On FibroGen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FGEN. JPMorgan Chase & Co. raised its holdings in shares of FibroGen by 430.7% during the third quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock worth $668,000 after acquiring an additional 1,358,194 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of FibroGen by 139.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock worth $1,179,000 after purchasing an additional 769,586 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of FibroGen during the 3rd quarter worth about $307,000. Cubist Systematic Strategies LLC lifted its holdings in shares of FibroGen by 3,906.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 280,161 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of FibroGen in the 2nd quarter valued at approximately $145,000. Institutional investors and hedge funds own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.